scholarly journals Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Drugs ◽  
2020 ◽  
Author(s):  
Tony S. Mok ◽  
Ying Cheng ◽  
Xiangdong Zhou ◽  
Ki Hyeong Lee ◽  
Kazuhiko Nakagawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Activating Mutations ◽  
First Line Treatment

scholarly journals Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients

2014 ◽  
Vol 9 (5) ◽  
pp. 733-737 ◽  
Author(s):  
Cesare Gridelli ◽  
Silvia Novello ◽  
Nicoletta Zilembo ◽  
Andrea Luciani ◽  
Adolfo Gino Favaretto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Randomized Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer

2019 ◽  
Vol 21 (3) ◽  
pp. 17-20
Author(s):  
Elena V Reutova ◽  
Konstantin P Laktionov ◽  
Denis I Iudin ◽  
Lidiia A Neliubina ◽  
Galina K Gorokhova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Malignant Neoplasms ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

In the past century, lung cancer has become one of the most prevalent malignant neoplasms. The prognosis for patients with metastatic and locally advanced non-small cell lung cancer (NSCLC) was extremely pessimistic. The overall survival on standard platinum-based chemotherapy did not exceed 10 months. The treatment tactics choice, namely choice of specific chemotherapeutic regimen, was empirical. The situation has changed dramatically with the study of molecular-genetic disorders that contribute to a tumor development and targeted therapy availability. Until recently, the main approach to the treatment of patients with NSCLC with activating mutations was the use of first-generation tyrosine kinase inhibitors (TKI), then, in the case of disease progression, the administration of next generations drugs or chemotherapy. However, this trend has been changing lately, new generation of targeted drugs have a significant advantage in time till progression, better intracranial control, a more favorable safety profile, that establish them as first-line treatment. Recent data confirms also an improvement of overall survival. This article discusses the situation in EGFR-postive NSCLC.

Real-world outcomes for patients with metastatic non-small cell lung cancer according to first-line treatment

2021 ◽  
Vol 69 ◽  
pp. S36
Author(s):  
Y. Belaroussi ◽  
S. Cousin ◽  
M. Carton ◽  
M. Lebitasy ◽  
L. Laborde ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document